An experimental antibody therapy is being studied for its potential to help clear stubborn lung infections in cystic fibrosis.
#CysticFibrosis #CFResearch #ClinicalTrials #LungHealth #CFScience #RareDiseaseResearch #CysticFibrosisNewsToday #Bionews
An experimental antibody therapy is being studied for its potential to help clear stubborn lung infections in cystic fibrosis.
#CysticFibrosis #CFResearch #ClinicalTrials #LungHealth #CFScience #RareDiseaseResearch #CysticFibrosisNewsToday #Bionews
#PhD #Microbiology #CF #CFResearch #PULSECF
#PhD #Microbiology #CF #CFResearch #PULSECF
A new study reports that one in four children hospitalized with severe cystic fibrosis flareups experienced temporary pulmonary hypertension.
#CysticFibrosis #CysticFibrosisNewsToday #Bionews #CFResearch #PulmonaryHealth
A new study reports that one in four children hospitalized with severe cystic fibrosis flareups experienced temporary pulmonary hypertension.
#CysticFibrosis #CysticFibrosisNewsToday #Bionews #CFResearch #PulmonaryHealth
PSI funds grantees who are advancing research to improve outcomes for people living with #CysticFibrosis in Ontario and beyond.
Check out our grantees' studies:
#CFAwarenessMonth #CFResearch
PSI funds grantees who are advancing research to improve outcomes for people living with #CysticFibrosis in Ontario and beyond.
Check out our grantees' studies:
#CFAwarenessMonth #CFResearch
#CysticFibrosis #HealthEquity #CFResearch
#CysticFibrosis #HealthEquity #CFResearch
More than $6 million has been raised to support cystic fibrosis research, care, and advocacy.
#CysticFibrosis #CysticFibrosisNewsToday #CFAwareness #CFResearch #RareDisease #HealthNews #MedicalResearch #Bionews
More than $6 million has been raised to support cystic fibrosis research, care, and advocacy.
#CysticFibrosis #CysticFibrosisNewsToday #CFAwareness #CFResearch #RareDisease #HealthNews #MedicalResearch #Bionews
New research suggests Trikafta improved lung function and reduced flare ups in people with cystic fibrosis who started treatment after age 40.
#CysticFibrosis #CysticFibrosisNewsToday #Bionews #CFResearch #CFCommunity #RareDiseaseNews #CFTreatment
New research suggests Trikafta improved lung function and reduced flare ups in people with cystic fibrosis who started treatment after age 40.
#CysticFibrosis #CysticFibrosisNewsToday #Bionews #CFResearch #CFCommunity #RareDiseaseNews #CFTreatment
Read More: www.sciencedirect.com/science/arti...
Read More: www.sciencedirect.com/science/arti...
New research suggests CFTR mutations may contribute to CF related diabetes by directly affecting how the pancreas works, not just through mucus related damage.
#CysticFibrosis #CysticFibrosisNewsToday #CFResearch #CFDiabetes #CFRD #Bionews
New research suggests CFTR mutations may contribute to CF related diabetes by directly affecting how the pancreas works, not just through mucus related damage.
#CysticFibrosis #CysticFibrosisNewsToday #CFResearch #CFDiabetes #CFRD #Bionews
New research suggests specialized lung MRI scans may do a better job than standard breathing tests at predicting flare-ups in people with cystic fibrosis.
#CysticFibrosis #CFNews #CysticFibrosisNewsToday #Bionews #CFResearch #LungHealth
New research suggests specialized lung MRI scans may do a better job than standard breathing tests at predicting flare-ups in people with cystic fibrosis.
#CysticFibrosis #CFNews #CysticFibrosisNewsToday #Bionews #CFResearch #LungHealth
A study suggests GLP-1 medications, commonly used for diabetes and weight management, may improve lung function in some people with cystic fibrosis, even as weight decreases.
#CysticFibrosis #CysticFibrosisNewsToday #CFResearch #Bionews
A study suggests GLP-1 medications, commonly used for diabetes and weight management, may improve lung function in some people with cystic fibrosis, even as weight decreases.
#CysticFibrosis #CysticFibrosisNewsToday #CFResearch #Bionews
An inhaled investigational treatment showed encouraging safety results in a Phase 1 trial and remained in the lungs longer than expected.
#CysticFibrosis #CFResearch #ClinicalTrials #RareDiseaseResearch #CFNews #CysticFibrosisNewsToday #Bionews
An inhaled investigational treatment showed encouraging safety results in a Phase 1 trial and remained in the lungs longer than expected.
#CysticFibrosis #CFResearch #ClinicalTrials #RareDiseaseResearch #CFNews #CysticFibrosisNewsToday #Bionews
A new FDA approval is making treatment more affordable for people with cystic fibrosis.
#CysticFibrosisNews #CFCommunity #Tobramycin #CFResearch #CysticFibrosis #CFWarrior #CFStrong #Bionews #RareDiseaseCommunity
A new FDA approval is making treatment more affordable for people with cystic fibrosis.
#CysticFibrosisNews #CFCommunity #Tobramycin #CFResearch #CysticFibrosis #CFWarrior #CFStrong #Bionews #RareDiseaseCommunity
Protein production, or class 1, mutations stop the CFTR protein from being made. These include nonsense and splicing mutations, found in about 10% of people with cystic fibrosis.
#CysticFibrosis #CFResearch #CysticFibrosisNewsToday #Bionews
Protein production, or class 1, mutations stop the CFTR protein from being made. These include nonsense and splicing mutations, found in about 10% of people with cystic fibrosis.
#CysticFibrosis #CFResearch #CysticFibrosisNewsToday #Bionews
#PhD #Microbiome #CF #CFResearch #PULSECF
#PhD #Microbiome #CF #CFResearch #PULSECF